Osimertinib has been the standard treatment for advanced Epidermal Growth Factor Receptor (EGFR)-driven non-small cell lung cancer (NSCLC) for many years. However, even with remarkable response rate, progression-free survival (PFS) and survival benefit as compared to the old generation EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, treatment outcomes for these subsets of patients remain a challenge. Recently, in order to go beyond osimertinib, new treatment strategies have been developed. In particular, in the FLAURA 2 phase III randomized trial, the combination of platin-based chemotherapy and osimertinib showed impressive PFS benefits as compared to single-agent osimertinib. Furthermore, in the MARIPOSA phase III randomized study, the combination of the anti-EGFR and anti-MET monoclonal antibody amivantamab combined with the new anti-EGFR TKI lazertinib demonstrated remarkable PFS benefit as compared to single agent osimertinib. This paper will discuss these new treatment options and potential selection criteria for personalized treatment of patients.
奥希替尼多年来一直是治疗表皮生长因子受体（EGFR）驱动型晚期非小细胞肺癌（NSCLC）的标准疗法。然而，尽管相较于第一代EGFR酪氨酸激酶抑制剂（TKIs）吉非替尼和厄洛替尼，其缓解率、无进展生存期（PFS）及生存获益均有显著提升，但针对此类患者的治疗成效仍面临挑战。近期，为突破奥希替尼的疗效瓶颈，新的治疗策略相继涌现。特别是在FLAURA 2三期随机试验中，铂类化疗联合奥希替尼方案相较于奥希替尼单药治疗，展现出令人瞩目的PFS获益。此外，MARIPOSA三期随机研究显示，抗EGFR与抗MET双特异性单抗amivantamab联合新型抗EGFR TKI药物lazertinib的治疗方案，相比奥希替尼单药治疗亦表现出显著的PFS优势。本文将探讨这些新兴治疗方案及其在个体化治疗中的潜在选择标准。
肿瘤(癌症)患者之家